Through this symposium, we will discuss the latest updates from the 2024 ASCO congress. In metastatic EGFR-mutant non-small cell lung cancer (NSCLC), first-line treatment primarily involves EGFR tyrosine kinase inhibitors (TKIs). Selecting the appropriate TKI and considering TKI combination therapies in suitable patients may enhance treatment efficacy and outcomes. For second line and beyond, we will discuss emerging strategies that have shown promising trial results recently. These include novel mechanisms such as bi-specific antibodies and antibody-drug conjugates.